Skip to main content

Adjuvant Therapy in Gallbladder Cancers

  • Chapter
  • First Online:
Gallbladder Cancer
  • 357 Accesses

Abstract

Surgical resection remains the primary curative treatment for gallbladder cancers (GBC). Adjuvant chemotherapy should be offered in all patients of radically resected GBC (except pT1a) due to high rates of both local and distant recurrence even after complete surgical resection. Adjuvant chemotherapy improves overall survival in such patients. There is role of chemoradiation in margin-positive and node-positive disease. Due to lack of randomized trials comparing adjuvant chemotherapy versus adjuvant chemoradiation (CRT), the best treatment strategy for high-risk patients is still not established. This chapter summarizes the adjuvant treatment modalities and the evidence supporting the use of adjuvant therapy in GBC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.

    Article  Google Scholar 

  2. Jung SJ, Woo SM, Park HK, Lee WJ, Han MA, Han SS, et al. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology. 2012;83(2):83–90.

    Article  Google Scholar 

  3. Barreto SG, Pawar S, Shah S, Talole S, Goel M, Shrikhande SV. Patterns of failure and determinants of outcomes following radical re-resection for incidental gallbladder cancer. World J Surg. 2014;38(2):484–9.

    Article  Google Scholar 

  4. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.

    Article  Google Scholar 

  5. Ma N, Cheng H, Qin B, Zhong R, Wang B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer. 2015;15:615.

    Article  Google Scholar 

  6. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Study Group of Surgical Adjuvant Therapy for carcinomas of the pancreas and biliary tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.

    Article  Google Scholar 

  7. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.

    Article  CAS  Google Scholar 

  8. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.

    Article  CAS  Google Scholar 

  9. Kayahara M, Nagakawa T. Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients. Cancer. 2007;110(3):572–80.

    Article  Google Scholar 

  10. Park HS, Lim JY, Yoon DS, Park JS, Lee DK, Lee SJ, Choi HJ, Song SY, Lee WJ, Cho JY. Outcome of adjuvant therapy for gallbladder cancer. Oncology. 2010;79(3–4):168–73.

    Article  CAS  Google Scholar 

  11. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg. 2011;15(6):1007–16.

    Article  Google Scholar 

  12. Mantripragada KC, Hamid F, Shafqat H, Olszewski AJ. Adjuvant therapy for resected gallbladder cancer: analysis of the National Cancer Data Base. J Natl Cancer Inst. 2016;109(2):djw202.

    Article  Google Scholar 

  13. Bergquist JR, Shah HN, Habermann EB, Hernandez MC, Ivanics T, Kendrick ML, et al. Adjuvant systemic therapy after resection of node positive gallbladder cancer: time for a well-designed trial? (results of a US-national retrospective cohort study). Int J Surg. 2018;52:171–9.

    Article  Google Scholar 

  14. Kemp Bohan PM, Kirby DT, Chick RC, Bader JO, Clifton GT, Vreeland TJ, et al. Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefits in node-positive patients. Ann Surg Oncol. 2021;28(3):1466–80.

    Article  Google Scholar 

  15. Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol. 2007;96(1):8–13.

    Article  Google Scholar 

  16. Wang SJ, Fuller CD, Kim JS, Sittig DF, Thomas CR Jr, Ravdin PM. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 2008;26(13):2112–7.

    Article  Google Scholar 

  17. Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;29(35):4627–32.

    Article  Google Scholar 

  18. Kim WS, Choi DW, You DD, Ho CY, Heo JS, Choi SH. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010;14(4):679–87.

    Article  Google Scholar 

  19. Itoh H, Nishijima K, Kurosaka Y, Takegawa S, Kiriyama M, Dohba S, et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci. 2005;50(12):2231–42.

    Article  Google Scholar 

  20. Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2009;75(1):150–5.

    Article  CAS  Google Scholar 

  21. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant Capecitabine and gemcitabine followed by radiotherapy and concurrent Capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.

    Article  CAS  Google Scholar 

  22. Kim TH, Woo SM, Lee WJ, Oh ES, Youn SH, Moon SH, et al. Benefit of adjuvant chemoradiotherapy in resected gallbladder carcinoma. Sci Rep. 2019;9(1):11770.

    Article  Google Scholar 

  23. Mitin T, Enestvedt CK, Jemal A, Sineshaw HM. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst. 2017;109(7).

    Google Scholar 

  24. Ren B, Guo Q, Yang Y, Liu L, Wei S, Chen W, Tian Y. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol. 2020;15(1):15.

    Article  Google Scholar 

  25. Bosset JF, Mantion G, Gillet M, Pelissier E, Boulenger M, Maingon P, et al. Primary carcinoma of the gallbladder. Adjuvant postoperative external irradiation. Cancer. 1989;64(9):1843–7.

    Article  CAS  Google Scholar 

  26. Mahe M, Stampfli C, Romestaing P, Salerno N, Gerard JP. Primary carcinoma of the gall-bladder: potential for external radiation therapy. Radiother Oncol. 1994;33(3):204–8.

    Article  CAS  Google Scholar 

  27. Todoroki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y, et al. Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology. 1999;46(27):1585–91.

    CAS  Google Scholar 

  28. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(1):167–75.

    Article  Google Scholar 

  29. Lindell G, Holmin T, Ewers SB, Tranberg KG, Stenram U, Ihse I. Extended operation with or without intraoperative (IORT) and external (EBRT) radiotherapy for gallbladder carcinoma. Hepatogastroenterology. 2003;50(50):310–4.

    Google Scholar 

  30. Czito BG, Hurwitz HI, Clough RW, Tyler DS, Morse MA, Clary BM, et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 2005;62(4):1030–4.

    Article  Google Scholar 

  31. Balachandran P, Agarwal S, Krishnani N, Pandey CM, Kumar A, Sikora SS, et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 2006;10(6):848–54.

    Article  Google Scholar 

  32. Cho SY, Kim SH, Park SJ, Han SS, Kim YK, Lee KW, et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol. 2010;102:87–93.

    Article  Google Scholar 

  33. Lee HY, Kim YH, Jung GJ, RohYH PSY, Kang NU, et al. Prognostic factors for gallbladder cancer in the laparoscopy era. J Korean Surg Soc. 2012;83(4):227–36.

    Article  Google Scholar 

  34. Müller B, Sola JA, Carcamo M, Ciudad AM, Trujillo C, Cerda B. Adjuvant chemoradiation for resected gallbladder cancer: treatment strategies for one of the leading causes of cancer death in Chilean women. Indian J Cancer. 2013;50(3):184–8.

    Article  Google Scholar 

  35. Gu B, Qian L, Yu H, Hu J, Wang Q, Shan J, et al. Concurrent Chemoradiotherapy in curatively resected gallbladder carcinoma: a propensity score-matched analysis. Int J Radiat Oncol Biol Phys. 2018;100(1):138–45.

    Article  Google Scholar 

  36. Agrawal S, Alam MN, Rastogi N, Saxena R. Evolution of adjuvant therapy in radically resected carcinoma gallbladder (GBC) over a decade: a real world experience from a Regional Cancer Centre. Ann Oncol. 2020;31:S264.

    Article  Google Scholar 

  37. Agrawal S, Saxena R. Extended field postoperative radiotherapy (EFRT) yields better outcomes as compared to localised field RT (LFRT) in radically resected gallbladder cancer (GBC). Asia Pac J Cancer Care. 2020;5(4):287–93.

    Article  Google Scholar 

  38. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27.

    Article  Google Scholar 

  39. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Accessed 6 Jun 2021.

    Google Scholar 

  40. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. ESMO guidelines committee. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–37.

    Article  CAS  Google Scholar 

  41. Pandey P, Pandey M, Singh KK, Dixit R, Shukla VK. Health related quality of life in patients of the gallbladder cancer with treatment. Int J Biol Med Res. 2017;8(2):5948–53.

    Google Scholar 

  42. Dwivedi AND, Jain S, Dixit R. Gallbladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases. 2015;3(3):231–44. https://doi.org/10.12998/wjcc.v3.i3.231.

    Article  Google Scholar 

  43. Agrawal S, Saxena R. Raised carbohydrate antigen 19-9 levels detect recurrences and impacts overall and disease-free survival in radically resected gallbladder cancer: a simple surveillance marker? J Cancer Res Ther. 2021.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khosla, D., Agrawal, S. (2023). Adjuvant Therapy in Gallbladder Cancers. In: Kumar Shukla, V., Pandey, M., Dixit, R. (eds) Gallbladder Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-19-6442-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-6442-8_9

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-6441-1

  • Online ISBN: 978-981-19-6442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics